Several advisory panel members discussed whether 16 and 17 year olds should be included in the recommendation. In the end, they voted on the question as put them by the FDA, which included 16 to 17 year olds. The FDA said during the panel meeting that there was not enough data to support or contradict use of the vaccine in pregnant women. Pfizer believes it should offer the vaccine to people in the placebo group of its trial as they become eligible for the shot. Nevertheless, an FDA official said the agency has asked Pfizer to add severe allergic reactions to their plans to study safety issues related to the vaccine once it’s authorized.

Source: Dhaka Tribune December 11, 2020 02:37 UTC